ClinicalTrials.gg
CompletedNCT02500043Updated Sep 3, 2024Results posted

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

A Phase 3 interventional study of TAS-102 and Placebo in Refractory Metastatic Gastric Cancer, sponsored by Taiho Oncology, Inc.. Completed at 139 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Stomach Neoplasms · Otsuka Holdings Co., Ltd..

Enrollment
5th of 13
507 · median 407
Started
2016
the only one that year
Phase 3
8 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 3, and was the 12th registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

1 of the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.

Read the detailed description

This is a multinational, double-blind, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of TAS-102 plus BSC versus placebo plus BSC in participants with metastatic gastric cancer who have previously received at least 2 prior regimens for advanced disease. Eligible participants will be centrally randomized (2:1) to TAS-102 + BSC (experimental arm) or placebo + BSC (control arm).

03

Conditions studied

  • Refractory Metastatic Gastric Cancer

Browse trials for

Keywords

  • Gastric Cancer
  • Metastatic Gastric Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has confirmed non-resectable, gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.
  2. Has previously received at least 2 prior regimens for advanced disease and were to or unable to tolerate their last prior therapy.
  3. Has measureable or nonmeasurable disease as defined by (RECIST) 1.1 criteria.
  4. Is able to take medications orally (ie, no feeding tube).
  5. Has an performance status of 0 or 1.
  6. Has adequate organ function as defined by protocol defined labs.
  7. Women of must have a negative pregnancy test and must agree to adequate if conception is possible. Males must agree to adequate birth control.

Exclusion criteria

Exclusion Criteria:

  1. Has certain serious illnesses or medical conditions
  2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received agent within the specified time frames prior to study drug administration.
  3. Has previously received TAS-102.
  4. Has unresolved toxicity of greater than or equal to Grade 2 attributed to any prior therapies.
  5. Is a pregnant or lactating female.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    TAS-102+BSC

    Participants received 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.

    Drug: TAS-102

  • Experimental
    Placebo+BSC

    Participants received 35 mg/m\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.

    Drug: Placebo

Interventions

  • DrugTAS-102

    35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.

  • DrugPlacebo

    35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death were censored at last follow-up or cut-off date, whichever comes first. OS was estimated by Kaplan-Meier method.

    Time frame: From the date of randomization to the data cut-off date (maximum duration: up to approximately 46 months)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for target lesions were defined as target lesions with at least 20 % relative increase in the sum of diameters with reference to the smallest sum on study, including the baseline sum and this sum demonstrated an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions or Unequivocal progression of existing non-target lesions. All alive participants with no disease progression as of the analysis cut-off date were censored at the last tumor assessment. PFS was estimated by Kaplan-Meier method.

    Time frame: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)

    Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study medication was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs/TESAEs were defined as events that started on or after treatment or started before treatment and worsened after the start of treatment through 30 days after the last dose of study treatment.

    Time frame: From the first dose of study treatment until 30 days after the last dose of study treatment (maximum duration: up to approximately 46 months)

Other outcomes

  1. Overall Response Rate (ORR)

    Overall response rate was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \< 10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference.

    Time frame: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks

  2. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD). The assessment of DCR was based on Investigator review of radiologic images and following RECIST criteria (version 1.1, 2009).

    Time frame: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks

  3. Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline

    The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0 = normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50% of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as a change from 0, 1 to \>=2, or from 2 to \>=3.

    Time frame: At the time of randomization (Day 1 Cycle 1) and within 24 hours prior to start of study treatment in every cycle (maximum duration: up to approximately 46 months)

  4. Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status

    EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) and other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health and QoL, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 and 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best QoL for participant.

    Time frame: Baseline, Day 1 Cycle 2 up to end of treatment (EOT) (within 30 days of last study treatment) and 30-Day safety follow-up visit (maximum duration: up to approximately 46 months)

  5. EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance

    The Quality of Life Questionnaire Stomach Cancer Module 22 (QLQ-STO22) assessed symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, dietary restrictions, pain QS22, reflux, and anxiety) and 4 single items (dry mouth, hair loss, taste problems, body image). Most questions use 4-point scale (1='Not at all', 2=a little, 3=quite a bit and 4='Very much'). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100, where higher score=better level of functioning or greater degree of symptoms.

    Time frame: Baseline, Cycle 1 Day 1 up to end of treatment (EOT) (within 30 days of last study treatment) (maximum duration: up to approximately 46 months)

07

Results

Posted Sep 16, 2021

Participant flow

The study was conducted at study centers in 17 countries. Participants were involved in the study from 24 February 2016 to 19 December 2019.

Participant flow — Overall Study
MilestoneTAS-102+BSCPlacebo+BSC
Started337170
As-treated (at) population335168
Completed00
Not completed337170
Withdrew: Randomized, but not treated22
Withdrew: Ongoing at date of cut-off193
Withdrew: Adverse event3311
Withdrew: Clinical progression5435
Withdrew: Radiological progression192110
Withdrew: Physician's decision113
Withdrew: Withdrawal by subject144
Withdrew: Death112
Withdrew: Protocol deviation10

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death were censored at last follow-up or cut-off date, whichever comes first. OS was estimated by Kaplan-Meier method.

Time frame:
From the date of randomization to the data cut-off date (maximum duration: up to approximately 46 months)
Reported as:
Median · months
Overall Survival (OS)
monthsTAS-102+BSCPlacebo+BSC
Overall Survival (OS)5.7 (4.8 to 6.2)3.6 (3.1 to 4.1)
Statistical analysis
  • TAS-102+BSC vs Placebo+BSC · Log Rank · p = 0.0003 (One-sided P-Value.) · Hazard ratio (hr): 0.6917 · 95% CI 0.5597 to 0.8548
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for target lesions were defined as target lesions with at least 20 % relative increase in the sum of diameters with reference to the smallest sum on study, including the baseline sum and this sum demonstrated an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions or Unequivocal progression of existing non-target lesions. All alive participants with no disease progression as of the analysis cut-off date were censored at the last tumor assessment. PFS was estimated by Kaplan-Meier method.

Time frame:
From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsTAS-102+BSCPlacebo+BSC
Progression-Free Survival (PFS)2.0 (1.9 to 2.3)1.8 (1.7 to 1.9)
Statistical analysis
  • TAS-102+BSC vs Placebo+BSC · Hazard ratio (hr): 0.5723 · 95% CI 0.4674 to 0.7008
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)

Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study medication was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs/TESAEs were defined as events that started on or after treatment or started before treatment and worsened after the start of treatment through 30 days after the last dose of study treatment.

Time frame:
From the first dose of study treatment until 30 days after the last dose of study treatment (maximum duration: up to approximately 46 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
ParticipantsTAS-102+BSCPlacebo+BSC
TEAE319151
TESAE14370
Other pre-specifiedOverall Response Rate (ORR)

Overall response rate was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \< 10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference.

Time frame:
From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsTAS-102+BSCPlacebo+BSC
Overall Response Rate (ORR)4.5 (2.4 to 7.5)2.1 (0.4 to 5.9)
Other pre-specifiedDisease Control Rate (DCR)

DCR was defined as the proportion of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD). The assessment of DCR was based on Investigator review of radiologic images and following RECIST criteria (version 1.1, 2009).

Time frame:
From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsTAS-102+BSCPlacebo+BSC
Disease Control Rate (DCR)44.1 (38.3 to 50.1)14.5 (9.2 to 21.3)
Other pre-specifiedTime to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline

The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0 = normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50% of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as a change from 0, 1 to \>=2, or from 2 to \>=3.

Time frame:
At the time of randomization (Day 1 Cycle 1) and within 24 hours prior to start of study treatment in every cycle (maximum duration: up to approximately 46 months)
Reported as:
Median · months
Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline
monthsTAS-102+BSCPlacebo+BSC
Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline4.3 (3.7 to 4.7)2.3 (2.0 to 2.8)
Other pre-specifiedChange From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) and other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health and QoL, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 and 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best QoL for participant.

Time frame:
Baseline, Day 1 Cycle 2 up to end of treatment (EOT) (within 30 days of last study treatment) and 30-Day safety follow-up visit (maximum duration: up to approximately 46 months)
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status
units on a scaleTAS-102+BSCPlacebo+BSC
Cycle 1-2.7 ± 17.56-5.9 ± 22.20
Cycle 2-5.9 ± 20.51-7.3 ± 25.80
Cycle 3-4.1 ± 18.26-1.4 ± 22.00
Cycle 4-3.6 ± 17.54-1.7 ± 22.32
Cycle 5-5.9 ± 18.0511.1 ± 18.16
Cycle 6-8.8 ± 23.0515.6 ± 21.10
Cycle 7-9.5 ± 21.9620.0 ± 4.56
Cycle 8-4.3 ± 23.8216.7 ± 11.79
Cycle 92.4 ± 17.1216.7 ± 16.67
Cycle 10-14.4 ± 25.5725.0 ± 11.79
Cycle 11-16.7 ± 37.2725.0 ± 11.79
Cycle 12-8.3 ± 11.7933.3
Cycle 130.033.3
Cycle 14—33.3
Cycle 15—33.3
Last Collection Cycle-8.8 ± 20.91-9.8 ± 25.34
Safety Follow-Up-16.5 ± 23.45-8.9 ± 18.33
Other pre-specifiedEORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance

The Quality of Life Questionnaire Stomach Cancer Module 22 (QLQ-STO22) assessed symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, dietary restrictions, pain QS22, reflux, and anxiety) and 4 single items (dry mouth, hair loss, taste problems, body image). Most questions use 4-point scale (1='Not at all', 2=a little, 3=quite a bit and 4='Very much'). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100, where higher score=better level of functioning or greater degree of symptoms.

Time frame:
Baseline, Cycle 1 Day 1 up to end of treatment (EOT) (within 30 days of last study treatment) (maximum duration: up to approximately 46 months)
Reported as:
Number · percentage of participants
EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance
percentage of participantsTAS-102+BSCPlacebo+BSC
Dysphagia86.678.2
Dietary Restrictions86.678.2
Pain QS2286.678.2
Reflux86.678.2
Anxiety86.678.2
Dry Mouth86.478.2
Body Image85.878.2
Hair Loss86.678.2
Taste Problems86.678.2

Adverse events

Collected over From first dose of study treatment up to 30 days of last study treatment (maximum duration: up to approximately 46 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAS-102+BSC252/335 (75.2%)143/335 (42.7%)319/335 (95.2%)
Placebo+BSC141/168 (83.9%)70/168 (41.7%)151/168 (89.9%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventTAS-102+BSCPlacebo+BSC
General physical health deteriorationGeneral disorders21/33515/168
AscitesGastrointestinal disorders3/3357/168
AnaemiaBlood and lymphatic system disorders13/3354/168
Abdominal painGastrointestinal disorders8/3356/168
Decreased appetiteMetabolism and nutrition disorders11/3354/168
VomitingGastrointestinal disorders9/3351/168
PancytopeniaBlood and lymphatic system disorders7/3350/168
DiarrhoeaGastrointestinal disorders6/3350/168
DysphagiaGastrointestinal disorders6/3352/168
Gastric haemorrhageGastrointestinal disorders3/3353/168
Most frequent other events
Showing 10 of 345
Most frequent other events
EventTAS-102+BSCPlacebo+BSC
AnaemiaBlood and lymphatic system disorders142/33530/168
NeutropeniaBlood and lymphatic system disorders128/3356/168
NauseaGastrointestinal disorders123/33553/168
Decreased appetiteMetabolism and nutrition disorders109/33549/168
FatigueGeneral disorders87/33535/168
VomitingGastrointestinal disorders80/33534/168
AstheniaGeneral disorders65/33537/168
DiarrhoeaGastrointestinal disorders73/33524/168
LeukopeniaBlood and lymphatic system disorders57/3353/168
Abdominal painGastrointestinal disorders50/33527/168

Baseline characteristics

Analysis was performed on the Intent-to-Treat (ITT) population that included all randomized participants, regardless of whether or not study treatment was administered.

Age, Continuous
Age, Continuous(Years)TAS-102+BSCPlacebo+BSCTotal
Mean62.8 ± 10.7862.0 ± 10.0462.5 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)TAS-102+BSCPlacebo+BSCTotal
Female8553138
Male252117369
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TAS-102+BSCPlacebo+BSCTotal
White244113357
Black/African American123
Asian512980
Not collectable382462
Other325
European Cooperative Oncology Group (ECOG) Performance Status
European Cooperative Oncology Group (ECOG) Performance Status(Participants)TAS-102+BSCPlacebo+BSCTotal
ECOG Grade 012368191
ECOG Grade 1214102316
08

Study locations

139 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Alta Bates Summit Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • St. Jude Heritage Healthcare
    Fullerton, California 92835, United States
  • Los Angeles Cancer Network
    Los Angeles, California 90017, United States
  • University of Southern California - Keck School of Medicine
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • California Pacific Medical Center
    San Francisco, California 94109, United States
  • 21st Century Oncology
    Jacksonville, Florida 32204, United States
  • Mount Sinai Hospital Medical Center
    Chicago, Illinois 60608, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Illinois CancerCare P.C.
    Peoria, Illinois 61615, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Dartmouth-Hitchcock Medical Center (DHMC)
    Lebanon, New Hampshire 03756, United States
  • Laura & Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Univeristy of Rochester Medical Center
    Rochester, New York 14642, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • University of Pittsburgh Medical Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Roger Williams Medical Center
    Providence, Rhode Island 02908, United States
  • Coastal Bend Cancer Center
    Corpus Christi, Texas 78404, United States
  • University of Wisconsin
    Madison, Wisconsin 53792-0001, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226-3522, United States
  • Gomel Regional Clinical Oncology Dispensary
    Gomel, 246012, Belarus
  • Minsk City Clinical Oncology Dispensary
    Minsk, 220013, Belarus
  • Republican center for oncology and medical radiology n.a. Alexandrov
    Minsk, 223040, Belarus
  • Clinique universitaire Saint Luc
    Brussels, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • University Hospital Antwerpen
    Edegem, B-2650, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Recherche GCP Research
    Montreal, H1M 1M1, Canada
  • Fakultni Nemocniceu sv. Anny v Brne
    Brno, 62100, Czechia
  • Faculty Hospital Hradec Kralove
    Hradec Králové, 50005, Czechia
  • Fakultní Nemocnice Olomouc
    Olomouc, 77520, Czechia
  • Nemocnice Na Homolce
    Praha, Czechia
  • VFN Praha
    Praha, Czechia
  • ICO Paul Papin
    Angers cedex 9, 49933, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Hopital de La Timone
    Marseille, 13005, France
  • Hôpital Saint Joseph
    Marseille, 13008, France
  • Centre Val D'Aurelle
    Montpellier, 34298, France
  • Hopital Europeen Georges Pompidou
    Paris, 75015, France
  • AP-HP - HU La Pitié-Salpêtrière - Charles-Foix
    Paris, 75651, France
  • Hôpital Saint-Jean
    Perpignan, 66000, France
  • Centre medico-chirurgical Magellan
    Pessac, 33604, France
  • Centre Eugène Marquis
    Rennes Cedex, 35042, France
  • Centre René Gauducheau
    Saint Herblain, France
  • Technische Universitaet Muenchen
    Muenchen, Bayern 81675, Germany
  • Charite Universitaetsmedizin Berlin
    Berlin, 13353, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Staedtisches Krankenhaus Muenchen Neuperlach
    Muenchen, 81737, Germany
  • Leopoldina-Krankenhaus
    Schweinfurt, 97422, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89081, Germany
  • The Adelaide and Meath Hospital, Dublin, Incorporating The National Children's Hospital
    Dublin 24, Ireland
  • St James Hospital
    Dublin, Ireland
  • Waterford Regional Hospital
    Waterford, Ireland
  • Soroka Medical Centre
    Beersheba, 8410101, Israel
  • Rambam healthcare campus
    Haifa, 31096, Israel
  • Wolfson Medical Center
    Holon, 5822012, Israel
  • Hadassah Ein Karem
    Jerusalem, 91120, Israel
  • Rabin MC Belinson Hospital
    Petah Tikva, 49100, Israel
  • Sheba Medical Center
    Ramat Gan, 52520, Israel
  • Tel Aviv Sourasky Medical Center
    Ramat Gan, 64239, Israel
  • IRCCS Centro di Riferimento Oncologico - Aviano
    Aviano (PN), 33081, Italy
  • Humanitas Gavazzeni
    Bergamo, 24125, Italy
  • Fondazione Poliambulanza Istituto Ospedaliero
    Brescia, 25124, Italy
  • Struttura Complessa di Oncologia
    Cremona, 26100, Italy
  • Azienda Ospedaliero - Universitaria Careggi
    Firenze, 50134, Italy
  • Azienda Ospedaliera San Martino
    Genova, 16132, Italy
  • IRCCS - Istituto Scientifico Romagnolo Per lo Studio e la Cura Dei Tumori (I.R.S.T.)
    Meldola (FC), 47014, Italy
  • A.O. Ospedale 'Niguarda Ca Granda'
    Milano, 20162, Italy
  • Istituto Europeo di Oncologia (IEO)
    Milan, 20141, Italy
  • A.O.U. Seconda Universita'degli Studi di Napoli
    Napoli, 80131, Italy
  • A.O.U. San Luigi Gonzaga
    Orbassano (TO), 10043, Italy
  • Azienda Ospedaliero Universitaria Pisana (AOUP)
    Pisa, 56126, Italy
  • A.O.R. San Carlo
    Potenza, 85100, Italy
  • Istituto Clinico Humanitas
    Rozzano (Mi), 20089, Italy
  • A.O. della Valtellina e della Valchiavenna Ospedale di Sondrio
    Sondrio, 23100, Italy
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Gunma Prefectural Cancer Center
    Ōta, Gunma 373-8550, Japan
  • Ibaraki Prefectural Central Hospital
    Kasama, Ibaraki 309-1793, Japan
  • Osaka National Hospital
    Osaka-shi, Osaka 540-0006, Japan
  • Osaka General Medical Center
    Osaka-shi, Osaka 558-8558, Japan
  • Sakai City Medical Center
    Sakai, Osaka 593-8304, Japan
  • Tochigi Cancer Center
    Utsunomiya, Tochigi 320-0834, Japan
  • Toyama University Hospital
    Tōyama, Toyama 930-0194, Japan
  • Iwate Medical University
    Morioka, 020-8505, Japan
  • Górnoslaskie Centrum Medyczne im. prof. Leszka Gieca
    Katowice, 40-635, Poland
  • Szpital Uniwersytecki w Krakowie
    Kraków, 31-531, Poland
  • Regionalny Osrodek Onkologiczny
    Lodz, 93-513, Poland
  • Szpital MSWiA i Warminsko - Mazurskim Centrum Onkologii w Olsztynie
    Olsztyn, 10-228, Poland
  • Opolskie centrum Onkologii
    Opole, 45-060, Poland
  • Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
    Warszawa, 02-781, Poland
  • Unidade Local de Saúde de Matosinhos E.P.E.- H. Pedro Hispano
    Matosinhos, Porto 4464-513, Portugal
  • Hospital Garcia de Orta, E.P.E.
    Almada, Setubal 2805-267, Portugal
  • SNS - Hospital Braga
    Braga, 4710-243, Portugal
  • Fundação Champalimaud
    Lisboa, 1400-038, Portugal
  • Hospital da Luz, S.A.
    Lisboa, 1500-650, Portugal

Showing the first 100 of 139 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tabernero J, Alsina M, Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Ando T, Yalcin S, Van Cutsem E, Sabater J, Skanji D, Leger C, Amellal N, Ilson DH. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer. 2020 Jul;23(4):689-698. doi: 10.1007/s10120-020-01053-9. Epub 2020 Mar 4. PubMed 32128634 ↗
  • Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 1;6(1):e193531. doi: 10.1001/jamaoncol.2019.3531. Epub 2020 Jan 9. PubMed 31600365 ↗
  • Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalcin S, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum In: Lancet Oncol. 2018 Dec;19(12):e668. doi: 10.1016/S1470-2045(18)30843-X. PubMed 30355453 ↗
  • Bando H, Doi T, Muro K, Yasui H, Nishina T, Yamaguchi K, Takahashi S, Nomura S, Kuno H, Shitara K, Sato A, Ohtsu A. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer. 2016 Jul;62:46-53. doi: 10.1016/j.ejca.2016.04.009. Epub 2016 May 19. PubMed 27208903 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Apr 2018, 26 months.

Results were first posted in Sep 2021, 3 years 4 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 26 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Jul 16, 2015
StartActual
Feb 24, 2016
Primary completionActual
Apr 30, 2018
CompletionActual
Dec 19, 2019
Results first posted
Sep 16, 2021
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02500043
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Feb 24, 2016
Primary completion
Apr 30, 2018
Completion
Dec 19, 2019
Results posted
Sep 16, 2021
Last update
Sep 3, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion